7.81
前日終値:
$7.81
開ける:
$7.84
24時間の取引高:
1.02M
Relative Volume:
1.61
時価総額:
$421.58M
収益:
$2.81M
当期純損益:
$-97.34M
株価収益率:
-4.943
EPS:
-1.58
ネットキャッシュフロー:
$-91.47M
1週間 パフォーマンス:
+10.00%
1か月 パフォーマンス:
+10.00%
6か月 パフォーマンス:
+92.84%
1年 パフォーマンス:
-12.05%
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
名前
Fulcrum Therapeutics Inc
セクター
電話
617-651-8851
住所
26 LANDSDOWNE STREET, CAMBRIDGE, MA
FULC を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
FULC
Fulcrum Therapeutics Inc
|
7.81 | 421.58M | 2.81M | -97.34M | -91.47M | -1.58 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
460.83 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
558.63 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
324.79 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
595.19 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
294.51 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-05-23 | アップグレード | Leerink Partners | Market Perform → Outperform |
2025-05-15 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
2024-09-13 | ダウングレード | H.C. Wainwright | Buy → Neutral |
2024-09-12 | ダウングレード | BofA Securities | Neutral → Underperform |
2024-09-12 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
2024-09-12 | ダウングレード | Leerink Partners | Outperform → Market Perform |
2024-09-12 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
2024-09-12 | ダウングレード | Stifel | Buy → Hold |
2024-09-09 | アップグレード | BofA Securities | Underperform → Neutral |
2024-05-20 | 開始されました | Cantor Fitzgerald | Overweight |
2024-03-13 | 開始されました | RBC Capital Mkts | Outperform |
2023-09-25 | 開始されました | Goldman | Neutral |
2023-08-23 | アップグレード | H.C. Wainwright | Neutral → Buy |
2023-08-22 | アップグレード | Stifel | Hold → Buy |
2023-05-04 | ダウングレード | Goldman | Buy → Neutral |
2023-03-10 | ダウングレード | Credit Suisse | Outperform → Neutral |
2023-03-10 | ダウングレード | H.C. Wainwright | Buy → Neutral |
2023-03-09 | ダウングレード | Stifel | Buy → Hold |
2023-02-28 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2023-02-24 | ダウングレード | BofA Securities | Neutral → Underperform |
2022-11-15 | 開始されました | Goldman | Buy |
2022-03-08 | 開始されました | Oppenheimer | Outperform |
2022-03-03 | アップグレード | BofA Securities | Underperform → Neutral |
2021-08-11 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2021-04-26 | 再開されました | Credit Suisse | Outperform |
2021-03-22 | 開始されました | Credit Suisse | Outperform |
2021-03-02 | 開始されました | Stifel | Buy |
2020-10-16 | 開始されました | Piper Sandler | Overweight |
2020-08-12 | ダウングレード | BofA Securities | Neutral → Underperform |
2020-08-12 | 繰り返されました | H.C. Wainwright | Buy |
2020-08-12 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2020-06-19 | ダウングレード | BofA/Merrill | Buy → Neutral |
2020-06-17 | 開始されました | BTIG Research | Buy |
2019-10-03 | 開始されました | H.C. Wainwright | Buy |
2019-08-12 | 開始されました | BofA/Merrill | Buy |
すべてを表示
Fulcrum Therapeutics Inc (FULC) 最新ニュース
Fulcrum Therapeutics to Present Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease - The Manila Times
Fulcrum Therapeutics stock soars ahead of sickle cell trial data By Investing.com - Investing.com Canada
Crucial Phase 1b Data Reveals Pociredir's Impact on Sickle Cell Disease at 12mg Dose Level - Stock Titan
Does Fulcrum Therapeutics Inc. qualify in momentum factor screeningFree Intraday Trend Analysis for Fast Gains - Newser
Key External Factors That Drive Fulcrum Therapeutics Inc. Stock Price MovementsMarket Opportunity Tracker for Swing Traders - Newser
Fulcrum Therapeutics (FULC) Projected to Post Quarterly Earnings on Wednesday - Defense World
Why is Fulcrum Therapeutics Inc. stock attracting strong analyst attentionGet alerts on high-potential stock breakouts - jammulinksnews.com
Is Fulcrum Therapeutics Inc. stock overvalued or undervaluedMaster stock selection with insider knowledge - jammulinksnews.com
Does Fulcrum Therapeutics Inc. stock perform well during market downturnsOutstanding growth strategies - jammulinksnews.com
Is Fulcrum Therapeutics Inc. a Top Dividend Stock to Watch in 2025Free Step-by-Step Investment Guide - Newser
why fulcrum therapeutics inc. stock attracts strong analyst attentionBreakout Confirmation Tool - Newser
Fulcrum Therapeutics Inc. Stock Analysis and ForecastGame-changing capital returns - PrintWeekIndia
What drives Fulcrum Therapeutics Inc. stock priceUnprecedented market success - PrintWeekIndia
What analysts say about Fulcrum Therapeutics Inc. stockFree Investment Portfolio Suggestions - Autocar Professional
What makes Fulcrum Therapeutics Inc. stock price move sharplyDefensive Stock Picks with Upside - Newser
Why Fulcrum Therapeutics Inc. stock attracts strong analyst attentionMassive Profit Potential - Newser
Will Fulcrum Therapeutics Inc. stock benefit from interest rate changesDynamic profit opportunities - jammulinksnews.com
Is Fulcrum Therapeutics Inc. a good long term investmentHigh-yield growth strategies - jammulinksnews.com
How Fulcrum Therapeutics Inc. stock performs during market volatilitySafe High Return Entry Points - Newser
Fulcrum Therapeutics (FULC) Drops 2.25% Despite 3.25% Intraday Gain - AInvest
Fulcrum Therapeutics Inc (FULC) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):